MSA Enters Joint Development Agreement

Pittsburgh, PA – April 9, 2013 – Management Science Associates, Inc. (MSA) today announced that it has entered into a joint development agreement with Mayo Clinic to extend MSA’s transplant software, EDIT™ (Electronic Data Interface for Transplantation), beyond solid organ transplantation to include a Blood and Marrow Transplantation (BMT) module. Additional efforts will focus on advancements in clinical usability for even greater clarity and speed in the execution of the transplant workflow process.
With the rapid evolution of solid organ, blood and marrow, and cell transplantation, the need for a premium integrated application and database is paramount. This is particularly the case when tracking and impacting outcomes for patients that receive both solid and non-solid transplantations. Clinical characteristics including demographics, disorders, source of organ or tissue and immunosuppressive drug regimens to defend against GVHD (graft-versus-host disease) and graft rejection are some of the focus areas of the joint development effort. Equally relevant will be the ability of the application to work across clinical disciplines and with outside parties, including relevant information transfer between cell therapy labs and interfacing with UNOS and CIBMTR registries.
MSA’s EDIT software was designed as a tool specifically for transplant departments and clinics. EDIT is a full-featured, clinical, data-management solution for the unique requirements of a transplant center. EDIT tracks patients through the entire transplantation process from initial referral through post-transplant follow-up by seamlessly interfacing with internal and external data sources and clinical registries to create a comprehensive view focused on transplantation. This comprehensive view is critical for patient care and required for research activities.
The teamwork with Mayo Clinic includes both development and testing efforts, ensuring effective collaborative expertise from both parties. Additionally, the integration of Mayo Clinic’s clinical know-how in the field of transplantation as a healthcare provider and developer of front-end solutions along with MSA’s ability to design, develop, promote, deliver and support software for healthcare providers will allow for a best-in-class solution.
“MSA is delighted to work with Mayo Clinic to combine our collective unique technologies and intellectual property in the evolution of EDIT into blood and marrow transplantation,” said Tony Fontecchio, MSA Vice President of the Life Sciences Division.
“We are delighted to collaborate with MSA for the development of a transplant management system for BMT and also for the update of EDIT. Transplantation of both solid organs and BMT is an ever-evolving clinical science requiring continuous adaptation of our electronic tools to facilitate and improve patient care. Our collaboration is founded upon this principle, and both Mayo Clinic and MSA have a common purpose of providing the very best possible care to patients,” said Dr. Fernando Cosio, Mayo Clinic.
“Today’s medical practice is dependent upon technology. We are excited to work together with MSA to jointly develop a system compatible for BMT,” said Dr. Roberta Adams, Mayo Clinic. “This joint development agreement is an example of how expertise in specialized patient care and expertise in software development are coming together to develop a patient management system for a specific patient population.”
About MSA
Management Science Associates, Inc. (MSA) is an international leader in the field of Information Science, specializing in developing new methods for the analysis, management and automation of information. MSA focuses its core competencies on business analysis, information technology and data management.
With 850 professionals, MSA provides solutions for over 300 clients, including some of the largest U.S. and foreign corporations and institutions. Headquartered in Pittsburgh, MSA also has offices in New York; Atlanta; High Point, NC; Las Vegas; Cardiff, UK; Shanghai, China and Kuala Lumpur, Malaysia.  More information about MSA can be found at
Mayo Clinic has a financial interest in the technology referenced in this news release.